Home>>Signaling Pathways>> Microbiology & Virology>> HCV>>Beclabuvir (BMS-791325)
Beclabuvir (BMS-791325) 目录号 GC33925

规格 价格 库存 购买数量
10mM*1mLinDMSO
¥4,535.00
现货
1mg
¥1,250.00
现货
5mg
¥3,124.00
现货
10mg
¥4,909.00
现货
25mg
¥9,818.00
现货
50mg
¥14,280.00
现货
100mg
¥21,420.00
现货

Customer Review

Based on customer reviews.

电话:400-920-5774 Email: sales@glpbio.cn

Sample solution is provided at 25 µL, 10mM.

Beclabuvir (BMS-791325) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Beclabuvir (BMS-791325) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 958002-33-0 SDF Download SDF
别名 N/A
化学名 N/A
Canonical SMILES O=C(N1C2CCC1CN(C)C2)[C@@]3(CN4C5=C(C6CCCCC6)C7=CC=C(C(NS(N(C)C)(=O)=O)=O)C=C47)[C@H](C8=CC(OC)=CC=C85)C3
分子式 C36H45N5O5S 分子量 659.84
溶解度 DMSO : ≥ 30 mg/mL (45.47 mM) 储存条件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

产品描述

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.

Beclabuvir demonstrates additive or synergistic antiviral activity with pegIFN/RBV and in 2- or 3-drug combinations with a range of DAAs, such as HCV NS3 protease inhibitors, NS5A inhibitors’ and/or nucleoside NS5B inhibitors[2].

The combination of beclabuvir with asunaprevir and daclatasvir achieves very high rates of viral eradication (about 90%) in patients infected with HCV genotype 1, which is the most common genotype worldwide[1].

[1]. Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21. [2]. Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22(8):658-64.